Ensysce Biosciences (ENSC) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 12, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38306
Entity Registrant Name	Ensysce Biosciences, Inc.
Entity Central Index Key	0001716947
Entity Tax Identification Number	82-2755287
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ENSC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		8,471,172
Entity Listing, Par Value Per Share	$ 0.0001

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,043,231	$ 1,123,604
Unbilled receivable	224,223	97,561
Prepaid expenses and other current assets	1,192,283	1,067,703
Total current assets	2,459,737	2,288,868
Other assets	335,883	419,217
Total assets	2,795,620	2,708,085
Current liabilities:
Accounts payable	481,971	1,936,007
Accrued expenses and other liabilities	370,186	542,260
Notes payable and accrued interest	454,463	854,697
Total current liabilities	1,306,620	3,332,964
Long-term liabilities:
Liability classified warrants	9,615	26,388
Total long-term liabilities	9,615	26,388
Total liabilities	1,316,235	3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2024 (unaudited) and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2024 (unaudited) and December 31, 2023; 8,151,253 and 3,146,157 shares issued at June 30, 2024 (unaudited) and December 31, 2023, respectively; 8,151,172 and 3,146,076 shares outstanding at June 30, 2024 (unaudited) and December 31, 2023, respectively	815	315
Additional paid-in capital	128,448,699	121,233,901
Accumulated deficit	(126,641,646)	(121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)	1,807,868	(322,858)
Noncontrolling interests in stockholders’ deficit	(328,483)	(328,409)
Total stockholders’ equity (deficit)	1,479,385	(651,267)
Total liabilities and stockholders’ equity (deficit)	$ 2,795,620	$ 2,708,085

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	8,151,253	3,146,157
Common stock, shares outstanding	8,151,172	3,146,076

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Federal grants	$ 181,797	$ 490,472	$ 487,519	$ 1,280,107
Operating expenses:
Research and development	947,229	1,643,726	1,726,133	3,439,742
General and administrative	1,190,010	1,140,700	2,559,791	2,695,553
Total operating expenses	2,137,239	2,784,426	4,285,924	6,135,295
Loss from operations	(1,955,442)	(2,293,954)	(3,798,405)	(4,855,188)
Other income (expense):
Change in fair value of convertible notes				146,479
Change in fair value of liability classified warrants	7,818	43,622	16,773	262,650
Interest expense, net	(27,563)		(1,275,628)	(1,497)
Other income, net	7,394	11,030	(27,096)	16,448
Total other income (expense), net	(12,351)	54,652	(1,285,951)	424,080
Net loss	(1,967,793)	(2,239,302)	(5,084,356)	(4,431,108)
Net loss attributable to noncontrolling interests		(7,060)	(74)	(11,001)
Deemed dividend related to warrants down round provision		3,729	290	12,038
Net loss attributable to common stockholders	$ (1,967,793)	$ (2,235,971)	$ (5,084,572)	$ (4,432,145)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic	$ (0.22)	$ (0.98)	$ (0.67)	$ (2.66)
Net loss per share attributable to common stockholders, diluted	$ (0.22)	$ (0.98)	$ (0.67)	$ (2.66)
Weighted average common shares outstanding, basic	8,817,316	2,274,113	7,640,192	1,667,527
Weighted average common shares outstanding, diluted	8,817,316	2,274,113	7,640,192	1,667,527

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 53	$ 107,216,566	$ (110,931,063)	$ (315,208)	$ (4,029,652)
Balance, shares at Dec. 31, 2022	534,490
Settlement of restricted stock units
Settlement of restricted stock units, shares	624
Public offerings, net	$ 139	9,049,865			9,050,004
Public offerings, net, shares	1,381,619
Transaction costs associated with public offerings		(447,879)			(447,879)
Issuance of common stock upon exercise of warrants	$ 30	(30)
Issuance of common stock upon exercise of warrants, shares	300,897
Stock-based compensation		194,550			194,550
Deemed dividend related to warrants down round provision		12,038	(12,038)
Net loss			(4,420,107)	(11,001)	(4,431,108)
Settlement of commitment fee	$ 4	399,996			400,000
Settlement of commitment fee, shares	44,444
Conversion of convertible notes	$ 41	3,056,851			3,056,892
Conversion of convertible notes, shares	408,580
Reverse split fractional shares
Reverse split fractional shares, shares	(862)
Balance at Jun. 30, 2023	$ 267	119,481,957	(115,363,208)	(326,209)	3,792,807
Balance, shares at Jun. 30, 2023	2,669,792
Balance at Mar. 31, 2023	$ 128	113,293,834	(113,127,237)	(319,149)	(152,424)
Balance, shares at Mar. 31, 2023	1,284,583
Settlement of restricted stock units
Settlement of restricted stock units, shares	312
Public offerings, net	$ 109	6,360,843			6,360,952
Public offerings, net, shares	1,084,000
Transaction costs associated with public offerings		(253,836)			(253,836)
Issuance of common stock upon exercise of warrants	$ 30	(30)
Issuance of common stock upon exercise of warrants, shares	300,897
Stock-based compensation		77,417			77,417
Deemed dividend related to warrants down round provision		3,729	(3,729)
Net loss			(2,232,242)	(7,060)	(2,239,302)
Balance at Jun. 30, 2023	$ 267	119,481,957	(115,363,208)	(326,209)	3,792,807
Balance, shares at Jun. 30, 2023	2,669,792
Balance at Dec. 31, 2023	$ 315	121,233,901	(121,557,074)	(328,409)	(651,267)
Balance, shares at Dec. 31, 2023	3,146,076
Settlement of restricted stock units
Settlement of restricted stock units, shares	63
Issuance of common stock upon exercise of warrants	$ 132	2,075,087			2,075,219
Issuance of common stock upon exercise of warrants, shares	1,323,904
Stock-based compensation		59,756			59,756
Deemed dividend related to warrants down round provision		290	(290)
Net loss			(5,084,282)	(74)	(5,084,356)
Issuance of common stock upon warrant inducement, net of issuance costs	$ 293	4,718,002			4,718,295
Issuance of common stock upon warrant inducement, net of issuance costs, shares	2,935,608
Conversion of convertible notes	$ 75	1,168,525			$ 1,168,600
Conversion of convertible notes, shares	745,521				745,521
Transaction costs associated with warrant inducement		(806,862)			$ (806,862)
Balance at Jun. 30, 2024	$ 815	128,448,699	(126,641,646)	(328,483)	1,479,385
Balance, shares at Jun. 30, 2024	8,151,172
Balance at Mar. 31, 2024	$ 733	128,422,232	(124,673,853)	(328,483)	3,420,629
Balance, shares at Mar. 31, 2024	7,329,172
Stock-based compensation		26,549			26,549
Net loss			(1,967,793)		(1,967,793)
Issuance of common stock upon warrant inducement, net of issuance costs	$ 82	(82)
Issuance of common stock upon warrant inducement, net of issuance costs, shares	822,000
Balance at Jun. 30, 2024	$ 815	$ 128,448,699	$ (126,641,646)	$ (328,483)	$ 1,479,385
Balance, shares at Jun. 30, 2024	8,151,172

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (5,084,356)	$ (4,431,108)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued interest and interest expense related to note conversions	29,113	1,497
Amortization of original issue discount and debt issuance costs	1,197,200
Change in fair value of convertible notes		(146,479)
Change in fair value of liability classified warrants	(16,773)	(262,650)
Stock-based compensation	59,756	194,550
Lease cost		(90)
Changes in operating assets and liabilities:
Unbilled receivable	(126,662)	169,243
Prepaid expenses and other assets	190,909	469,404
Accounts payable	(1,795,404)	(1,669,162)
Accrued expenses and other liabilities	(172,077)	(1,040,666)
Net cash used in operating activities	(5,718,294)	(6,715,461)
Cash flows from financing activities:
Proceeds public offering, net		9,050,004
Proceeds from warrant exercises	2,075,219
Proceeds from warrant inducement, net of issuance costs	4,718,295
Transaction costs associated with public offering		(447,879)
Transaction costs associated with warrant inducement	(465,494)
Repayment of convertible notes	(485,190)	(1,000,208)
Repayment of financed insurance premiums	(204,909)	(204,676)
Net cash provided by financing activities	5,637,921	7,397,241
Increase (decrease) in cash and cash equivalents	(80,373)	681,780
Cash and cash equivalents beginning of period	1,123,604	3,147,702
Cash and cash equivalents end of period	1,043,231	3,829,482
Supplemental disclosure of non-cash investing and financing activities:
Incremental fair value of February 2024 warrant inducement	5,167,372
Conversions of convertible notes into common stock	1,168,600	3,056,892
Transaction costs from warrant inducement	341,368
Deemed dividend related to warrants down round provision	290	12,038
Financed insurance premiums	235,155	445,737
Settlement of commitment fee in shares		$ 400,000

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its 79.2 ® ® In 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the certificate of incorporation, EBIR was authorized to issue 1,000,000 0.001 100,000 0.001 79.2 9.9 10.9 The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2023, which may be found in the Company’s Form 10-K filed with the SEC on March 15, 2024. Going concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates and assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services. Cash and cash equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as two research and development vendors made up greater than 10% individually, and 31 38 Property and equipment Property and equipment are fully depreciated and as such there is no Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of June 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. Warrants The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Liability classified warrants $ 9,615 $ - $ - $ 9,615 Total $ 9,615 $ - $ - $ 9,615 Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants 26,388 - - 26,388 Total $ 26,388 $ - $ - $ 26,388 The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024): SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Liability Fair value, December 31, 2023 $ 26,388 Change in fair value (16,773 ) Fair value, June 30, 2024 $ 9,615 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR ® 10.7 In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $ 5.4 1.9 The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 MPAR $ - $ 437,263 $ - $ 918,542 TAAP/OUD 181,797 53,209 487,519 361,565 Total $ 181,797 $ 490,472 $ 487,519 $ 1,280,107 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded. Research and development costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and administrative expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards. Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Net loss per share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period. The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Stock options 580,188 26,354 580,188 26,354 RSUs - 377 - 377 Warrants 11,005,004 3,017,026 10,373,633 1,938,542 Convertible notes 137,799 - 137,799 - Total 11,722,991 3,043,757 11,091,620 1,965,273 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS June 30, December 31, Prepaid research and development $ 539,208 $ 535,474 Prepaid insurance 418,215 441,871 Other prepaid expenses 170,439 72,358 Other current assets 64,421 18,000 Total prepaid expenses and other current assets $ 1,192,283 $ 1,067,703

ACCRUED EXPENSES AND OTHER LIAB

ACCRUED EXPENSES AND OTHER LIABILITIES	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, Accrued research and development $ 208,992 $ 329,228 Professional fees 26,950 110,202 Other accrued liabilities 134,244 102,830 Total accrued expenses and other liabilities $ 370,186 $ 542,260

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 – COMMITMENTS AND CONTINGENCIES Purchase Commitments As of June 30, 2024, the Company’s commitments included approximately $ 16 Litigation As of June 30, 2024, and December 31, 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Lease The Company’s current lease agreement (as amended) has a term that extends through October 31, 2024, with no contracted option to renew. As of June 30, 2024, the future lease payments totaled $ 11,363 8,747 17,495 8,375 16,749 Share Subscription Facility In December 2020, the Company executed the GEM Agreement, under which an investor agreed to provide the Company with a share subscription facility of up to $ 60.0 4,608 three 2,402.40 1.06

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE The following table provides a summary of the Company’s outstanding debt as of June 30, 2024: SCHEDULE OF DEBT Principal Accrued Net debt 2023 Notes $ 216,000 6,308 - 222,308 Financed insurance 232,155 - - 232,155 Total $ 448,155 $ 6,308 - $ 454,463 The following table provides a summary of the Company’s outstanding debt as of December 31, 2023: December 31, 2023 Principal Accrued Unamortized Debt Net debt 2023 Notes $ 1,836,000 $ 13,078 $ (1,197,200 ) $ 651,878 Financed insurance 197,249 5,570 - 202,819 Total $ 2,033,249 $ 18,648 $ (1,197,200 ) $ 854,697 Interest Expense The interest expense recognized for financed insurance was $ 148 2,092 0 1,497 27,563 1.3 2023 Notes On October 23, 2023, the Company entered into a Securities Purchase Agreement (“SPA”) for an aggregate financing of $ 1.8 0.2 612,000 566,667 1,255,697 0.0001 1,224,000 1,133,333 2,511,394 April 25, 2024 May 28, 2024 The combined notes are subject to an original issue discount of 8 6.0 1.5675 10 1.5675 0.1 0.3 The warrants have an exercise price of $ 1.5675 1.1 During 2024, the Company converted 745,521 1.2 1.0 0.5 0.5 Financed insurance premiums In June 2024, the Company renewed and financed its directors’ and officers’ liability insurance in the amount of $ 0.2

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY The Company’s current Certificate of Incorporation authorizes 250,000,000 1,500,000 0.0001 no 2024 Warrant Inducement On February 12, 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 3,601,752 3,601,752 1.31 3,601,752 3,601,752 1.06 1.06 May 12, 2028 4.7 5.2 In connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes’ SPA it had entered as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note 7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant inducement. The Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $ 0.3 the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 May 12, 2028 1.6375 The closing of the offering occurred on February 14, 2024. Abeyance Shares Related to the 2024 Warrant Inducement, a holder left 1,488,144 822,000 666,144 Warrants The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2024: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Exercise Description Classification (a) 63,659 $ 2,400.00 2,760.00 LACQ warrants Equity (b) 4,608 $ 1.31 Share subscription facility Equity (c) 4,518 $ 3.64 2021 Notes Liability (d) 38,900 $ 3.64 2022 Notes Liability (e) 549,993 $ 3.64 16.80 Public offering Equity (f) 318,451 $ 8.58 12.60 Public offering Equity (g) 126,061 $ 4.86 Public offering Equity (h) 2,443,187 $ 1.57 2023 Notes Equity (i) 7,455,627 $ 1.06 1.64 2024 Warrants Equity 11,005,004 (a) On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 7,782 7,310 2,400.00 2,760.00 June 30, 2026 five years 41,666 21,993 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 (b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 2,402.40 2,402.40 1.06 (c) On September 24, 2021 and November 5, 2021, the Company issued 1,507 3,011 1,831.20 September 23, 2026 November 4, 2026 187.20 0.125 3.64 (d) On July 1, 2022 and August 9, 2022, the Company issued 19,450 170.04 June 29, 2027 August 8, 2027 24.07 0.125 3.64 (e) On December 9, 2022, the Company issued 549,993 16.80 December 9, 2027. 0.125 166,667 3.64 (f) On February 6, 2023, the Company issued 318,451 8.58 12.60 February 2, 2028 August 7, 2028. (g) On May 12, 2023, the Company issued 3,727,813 3.64 4.86 November 12, 2024 May 10, 2028 May 12, 2028 3,601,752 1.31 (h) On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 2,511,394 1.5675 October 25, 2028 November 28, 2028 1,323,904 1.5675 (i) On February 12, 2024, the Company issued 7,455,627 1.06 August 14, 2025 May 12, 2028 1.6375 May 12, 2028 The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) $ 3,477.60 $ 2,400.00 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) $ 3,477.60 $ 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) $ 1.13 1,029.60 $ 1.06 680.23 0.38 2.58 91.3 140.5 1.04 5.43 (c) Liability classified warrants (grant date 9/24/21) $ 1,077.60 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) $ 540 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 6/30/24) $ 0.50 $ 3.64 2.25 2.35 133.7 135.4 4.6 % (d) Liability classified warrants (grant date 7/1/22) $ 136.80 $ 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) $ 127.20 $ 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 6/30/24) $ 0.50 $ 3.64 3.00 3.11 126.7 128.6 4.4 %

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 - STOCK-BASED COMPENSATION In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2023, the Company’s Board approved an annual increase of 26,725 585,796 The Company recognized stock-based compensation expense within general and administrative expense of $ 18,658 42,146 60,394 156,663 7,891 17,610 17,023 37,887 Option Activity There were no stock options granted during the six months ended June 30, 2024 and June 30, 2023. The following table summarizes the Company’s stock option activity during the six months ended June 30, 2024: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2023 581,314 $ 33.15 9.57 $ - Granted - - - - Exercised - - - - Expired / Forfeited - - - - Outstanding at June 30, 2024 581,314 33.15 9.08 - Exercisable at June 30, 2024 580,188 32.28 - - Vested and expected to vest 581,314 33.15 9.08 - Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in during the six months ended June 30, 2024 and 2023): ● Expected stock-price volatility. ● Expected term. ● Risk-free interest rate. ● Expected dividend yield. As of June 30, 2024, the Company had an aggregate of $ 60,092 0.95 Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE June 30, 2024 Awards outstanding under the 2021 Omnibus Incentive Plan 581,314 Awards available for future grant under 2021 Omnibus Incentive Plan 2,112 Warrants outstanding 11,005,004 Total shares of common stock reserved for future issuance 11,588,430

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 10 - RELATED PARTIES As of June 30, 2024, the Company held a $ 0.2 0.4 1.5675 April 25, 2025.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Use of estimates and assumptions	Use of estimates and assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.
Cash and cash equivalents	Cash and cash equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as two research and development vendors made up greater than 10% individually, and 31 38
Property and equipment	Property and equipment Property and equipment are fully depreciated and as such there is no
Fair Value Measurement	Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of June 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. Warrants The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Liability classified warrants $ 9,615 $ - $ - $ 9,615 Total $ 9,615 $ - $ - $ 9,615 Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants 26,388 - - 26,388 Total $ 26,388 $ - $ - $ 26,388 The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024): SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Liability Fair value, December 31, 2023 $ 26,388 Change in fair value (16,773 ) Fair value, June 30, 2024 $ 9,615 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR ® 10.7 In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $ 5.4 1.9 The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 MPAR $ - $ 437,263 $ - $ 918,542 TAAP/OUD 181,797 53,209 487,519 361,565 Total $ 181,797 $ 490,472 $ 487,519 $ 1,280,107 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded.
Research and development costs	Research and development costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and administrative expenses	General and administrative expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based compensation	Stock-based compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.
Income taxes	Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Net loss per share	Net loss per share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period. The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Stock options 580,188 26,354 580,188 26,354 RSUs - 377 - 377 Warrants 11,005,004 3,017,026 10,373,633 1,938,542 Convertible notes 137,799 - 137,799 - Total 11,722,991 3,043,757 11,091,620 1,965,273
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of June 30, 2024, and December 31, 2023. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Liability classified warrants $ 9,615 $ - $ - $ 9,615 Total $ 9,615 $ - $ - $ 9,615 Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants 26,388 - - 26,388 Total $ 26,388 $ - $ - $ 26,388
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3	The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2024 (no level 3 assets as of the six months ended June 30, 2024): SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Liability Fair value, December 31, 2023 $ 26,388 Change in fair value (16,773 ) Fair value, June 30, 2024 $ 9,615
SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS	The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 MPAR $ - $ 437,263 $ - $ 918,542 TAAP/OUD 181,797 53,209 487,519 361,565 Total $ 181,797 $ 490,472 $ 487,519 $ 1,280,107
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES	The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Stock options 580,188 26,354 580,188 26,354 RSUs - 377 - 377 Warrants 11,005,004 3,017,026 10,373,633 1,938,542 Convertible notes 137,799 - 137,799 - Total 11,722,991 3,043,757 11,091,620 1,965,273

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS June 30, December 31, Prepaid research and development $ 539,208 $ 535,474 Prepaid insurance 418,215 441,871 Other prepaid expenses 170,439 72,358 Other current assets 64,421 18,000 Total prepaid expenses and other current assets $ 1,192,283 $ 1,067,703

ACCRUED EXPENSES AND OTHER LI_2

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES	Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, Accrued research and development $ 208,992 $ 329,228 Professional fees 26,950 110,202 Other accrued liabilities 134,244 102,830 Total accrued expenses and other liabilities $ 370,186 $ 542,260

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	The following table provides a summary of the Company’s outstanding debt as of June 30, 2024: SCHEDULE OF DEBT Principal Accrued Net debt 2023 Notes $ 216,000 6,308 - 222,308 Financed insurance 232,155 - - 232,155 Total $ 448,155 $ 6,308 - $ 454,463 The following table provides a summary of the Company’s outstanding debt as of December 31, 2023: December 31, 2023 Principal Accrued Unamortized Debt Net debt 2023 Notes $ 1,836,000 $ 13,078 $ (1,197,200 ) $ 651,878 Financed insurance 197,249 5,570 - 202,819 Total $ 2,033,249 $ 18,648 $ (1,197,200 ) $ 854,697

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
SCHEDULE OF OUTSTANDING WARRANT	The following table provides a summary of outstanding warrants to purchase shares of common stock as of June 30, 2024: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Exercise Description Classification (a) 63,659 $ 2,400.00 2,760.00 LACQ warrants Equity (b) 4,608 $ 1.31 Share subscription facility Equity (c) 4,518 $ 3.64 2021 Notes Liability (d) 38,900 $ 3.64 2022 Notes Liability (e) 549,993 $ 3.64 16.80 Public offering Equity (f) 318,451 $ 8.58 12.60 Public offering Equity (g) 126,061 $ 4.86 Public offering Equity (h) 2,443,187 $ 1.57 2023 Notes Equity (i) 7,455,627 $ 1.06 1.64 2024 Warrants Equity 11,005,004 (a) On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 7,782 7,310 2,400.00 2,760.00 June 30, 2026 five years 41,666 21,993 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 (b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 2,402.40 2,402.40 1.06 (c) On September 24, 2021 and November 5, 2021, the Company issued 1,507 3,011 1,831.20 September 23, 2026 November 4, 2026 187.20 0.125 3.64 (d) On July 1, 2022 and August 9, 2022, the Company issued 19,450 170.04 June 29, 2027 August 8, 2027 24.07 0.125 3.64 (e) On December 9, 2022, the Company issued 549,993 16.80 December 9, 2027. 0.125 166,667 3.64 (f) On February 6, 2023, the Company issued 318,451 8.58 12.60 February 2, 2028 August 7, 2028. (g) On May 12, 2023, the Company issued 3,727,813 3.64 4.86 November 12, 2024 May 10, 2028 May 12, 2028 3,601,752 1.31 (h) On October 25, 2023 and November 28, 2023, the Company issued warrants to purchase 1,255,697 2,511,394 1.5675 October 25, 2028 November 28, 2028 1,323,904 1.5675 (i) On February 12, 2024, the Company issued 7,455,627 1.06 August 14, 2025 May 12, 2028 1.6375 May 12, 2028
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS	The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) $ 3,477.60 $ 2,400.00 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) $ 3,477.60 $ 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) $ 1.13 1,029.60 $ 1.06 680.23 0.38 2.58 91.3 140.5 1.04 5.43 (c) Liability classified warrants (grant date 9/24/21) $ 1,077.60 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) $ 540 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 6/30/24) $ 0.50 $ 3.64 2.25 2.35 133.7 135.4 4.6 % (d) Liability classified warrants (grant date 7/1/22) $ 136.80 $ 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) $ 127.20 $ 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 6/30/24) $ 0.50 $ 3.64 3.00 3.11 126.7 128.6 4.4 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes the Company’s stock option activity during the six months ended June 30, 2024: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2023 581,314 $ 33.15 9.57 $ - Granted - - - - Exercised - - - - Expired / Forfeited - - - - Outstanding at June 30, 2024 581,314 33.15 9.08 - Exercisable at June 30, 2024 580,188 32.28 - - Vested and expected to vest 581,314 33.15 9.08 -
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE	The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE June 30, 2024 Awards outstanding under the 2021 Omnibus Incentive Plan 581,314 Awards available for future grant under 2021 Omnibus Incentive Plan 2,112 Warrants outstanding 11,005,004 Total shares of common stock reserved for future issuance 11,588,430

ORGANIZATION AND PRINCIPAL AC_2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2020
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, par value	$ 0.0001	$ 0.0001
EBIR, Inc [Member]
Ownership percentage	79.20%
Common stock, shares authorized			1,000,000
Common stock, par value			$ 0.001
Preferred stock, shares authorized			100,000
Preferred stock, par value			$ 0.001
EBIR, Inc [Member] | Key Personnel [Member]
Ownership percentage	9.90%
EBIR, Inc [Member] | Unrelated Party [Member]
Ownership percentage	10.90%

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Liability classified warrants	$ 9,615	$ 26,388
Total	9,615	26,388
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Liability classified warrants	9,615	26,388
Total	$ 9,615	$ 26,388

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details) - Liability Classified Warrants [Member]	6 Months Ended
	Jun. 30, 2024 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 26,388
Change in fair value	(16,773)
Ending balance	$ 9,615

SCHEDULE OF REVENUE RECOGNITION

SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Product Information [Line Items]
Total	$ 181,797	$ 490,472	$ 487,519	$ 1,280,107
MPAR [Member]
Product Information [Line Items]
Total		437,263		918,542
TAAP/OUD [Member]
Product Information [Line Items]
Total	$ 181,797	$ 53,209	$ 487,519	$ 361,565

SCHEDULE OF WEIGHTED AVERAGE SH

SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11,722,991	3,043,757	11,091,620	1,965,273
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	580,188	26,354	580,188	26,354
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		377		377
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11,005,004	3,017,026	10,373,633	1,938,542
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	137,799		137,799

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2019
Product Information [Line Items]
Concentration of risk	two research and development vendors made up greater than 10% individually, and 31% and 38% in aggregate
Depreciation	$ 0	$ 0
Grants receivable	$ 1,900,000	$ 10,700,000	$ 5,400,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer [Member]
Product Information [Line Items]
Concentration of risk	31%	38%

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development	$ 539,208	$ 535,474
Prepaid insurance	418,215	441,871
Other prepaid expenses	170,439	72,358
Other current assets	64,421	18,000
Total prepaid expenses and other current assets	$ 1,192,283	$ 1,067,703

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued research and development	$ 208,992	$ 329,228
Professional fees	26,950	110,202
Other accrued liabilities	134,244	102,830
Total accrued expenses and other liabilities	$ 370,186	$ 542,260

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Feb. 12, 2024	Jan. 31, 2024	May 12, 2023	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021	Aug. 03, 2021	Jul. 02, 2021	Jun. 30, 2021	Dec. 31, 2020
Contractual obligation	$ 16,000,000		$ 16,000,000
Future lease payments			11,363
Rent expense	$ 8,747	$ 8,375	$ 17,495	$ 16,749
Common stock, subscriptions value															$ 60,000,000
Warrants issued shares								19,450	19,450	3,011	1,507		4,608	78,751
Warrant term													3 years	5 years
Warrant, exercise price	$ 1.06		$ 1.06		$ 1.31	$ 1.5675	$ 3.64	$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20	$ 2,400		$ 2,760
Investor [Member]
Warrants issued shares													4,608
Warrant term													3 years
Warrant, exercise price					$ 1.06								$ 2,402.40

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Principal balance	$ 448,155	$ 2,033,249
Accrued interest	6,308	18,648
Unamortized Debt Discount & Issuance Costs		(1,197,200)
Net debt balance	454,463	854,697
2023 Notes [Member]
Short-Term Debt [Line Items]
Principal balance	216,000	1,836,000
Accrued interest	6,308	13,078
Unamortized Debt Discount & Issuance Costs		(1,197,200)
Net debt balance	222,308	651,878
Financed Insurance [Member]
Short-Term Debt [Line Items]
Principal balance	232,155	197,249
Accrued interest		5,570
Unamortized Debt Discount & Issuance Costs
Net debt balance	$ 232,155	$ 202,819

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - $ / shares

Nov. 29, 2023

Jun. 30, 2021

Jun. 30, 2024

Feb. 12, 2024

Jan. 31, 2024

Dec. 31, 2023

Nov. 28, 2023

Oct. 25, 2023

Aug. 31, 2023

May 12, 2023

Feb. 06, 2023

Dec. 31, 2022

Dec. 09, 2022

Aug. 09, 2022

Jul. 31, 2022

Jul. 01, 2022

Nov. 05, 2021

Sep. 24, 2021

Aug. 03, 2021

Jul. 02, 2021

Short-Term Debt [Line Items]

Warrants issued

78,751

19,450

19,450

3,011

1,507

4,608

Warrants cancelled

7,310

7,782

Warrant exercise price

$ 2,760

$ 1.06

$ 1.31

$ 1.5675

$ 3.64

$ 170.04

$ 170.04

$ 1,831.20

$ 1,831.20

$ 2,400

Warrant expiration date

Jun. 30, 2026

Aug. 08, 2027

Jun. 29, 2027

Nov. 04, 2026

Sep. 23, 2026

Warrant term

5 years

3 years

Shares amended

250,000,000

250,000,000

Series B Warrants [Member]

Short-Term Debt [Line Items]

Warrants issued

3,601,752

Warrant exercise price

$ 1.06

Warrant expiration date

May 12, 2028

Series A Warrants [Member]

Short-Term Debt [Line Items]

Warrants issued

3,601,752

Warrant exercise price

$ 1.06

Warrant expiration date

Aug. 14, 2025

General and Administrative Expense [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 2,402.40

Public Warrant [Member]

Short-Term Debt [Line Items]

Class of warrant or right, outstanding

41,666

Private Warrant [Member]

Short-Term Debt [Line Items]

Remaining of cashless warrant shares

21,993

Warrant [Member]

Short-Term Debt [Line Items]

Warrants issued

3,601,752

1,323,904

2,511,394

1,255,697

3,727,813

318,451

549,993

Warrant exercise price

$ 1.5675

$ 1.6375

$ 1.5675

$ 1.5675

$ 0.125

$ 16.80

Warrant expiration date

May 12, 2028

Nov. 28, 2028

Oct. 25, 2028

Dec. 09, 2027

Shares amended

166,667

Warrant [Member] | Placement Agent Warrants [Member]

Short-Term Debt [Line Items]

Warrants issued

7,455,627

Warrant One [Member]

Short-Term Debt [Line Items]

Warrant expiration date

Feb. 02, 2028

Warrant Two [Member]

Short-Term Debt [Line Items]

Warrant expiration date

Aug. 07, 2028

Series A-1 Warrant [Member]

Short-Term Debt [Line Items]

Warrant expiration date

Nov. 12, 2024

Series A-2 Warrant [Member]

Short-Term Debt [Line Items]

Warrant expiration date

May 10, 2028

Placement Agent Warrants [Member]

Short-Term Debt [Line Items]

Warrant expiration date

May 12, 2028

Minimum [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 2,400

$ 2,402.40

Minimum [Member] | Warrant [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 3.64

$ 8.58

Maximum [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 2,760

Maximum [Member] | Warrant [Member]

Short-Term Debt [Line Items]

Warrant exercise price

4.86

$ 12.60

Subscription Arrangement [Member]

Short-Term Debt [Line Items]

Warrants issued

2,083

2023 Notes [Member] | First Securities Purchase Agreement [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

Apr. 25, 2024

2023 Notes [Member] | Second Securities Purchase Agreement [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

May 28, 2024

2022 Notes [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 187.20

2022 Notes and 2021 [Member]

Short-Term Debt [Line Items]

Warrant exercise price

$ 0.125

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 29, 2023	Oct. 25, 2023	Oct. 23, 2023	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Feb. 12, 2024	Jan. 31, 2024	Dec. 31, 2023	Nov. 28, 2023	May 12, 2023	Feb. 06, 2023	Dec. 09, 2022	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021	Aug. 03, 2021	Jul. 02, 2021	Jun. 30, 2021
Short-Term Debt [Line Items]
Interest expense					$ 148	$ 0	$ 2,092	$ 1,497
Aggregate principal amount				$ 448,155	$ 448,155		$ 448,155				$ 2,033,249
Warrants to purchase common shares																19,450	19,450	3,011	1,507		4,608	78,751
Common stock, par value				$ 0.0001	$ 0.0001		$ 0.0001				$ 0.0001
Warrant, exercise price				$ 1.06	$ 1.06		$ 1.06		$ 1.31	$ 1.5675			$ 3.64			$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20	$ 2,400		$ 2,760
Conversion of shares							745,521
Conversion of shares value							$ 1,168,600	3,056,892
Transaction cost							4,718,295
Warrant inducement cost							4,718,295
Transaction cost							(806,862)
Financed insurance premiums				$ 200,000			$ 235,155	$ 445,737
Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common shares		1,255,697							3,601,752	1,323,904		2,511,394	3,727,813	318,451	549,993
Warrant, exercise price		$ 1.5675		$ 1.5675	$ 1.5675		$ 1.5675		$ 1.6375			$ 1.5675	$ 0.125		$ 16.80
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate purchase price			$ 1,800,000
Warrant, exercise price			$ 1.5675
Transaction cost							$ 1,000,000
Warrant inducement cost							500,000
Transaction cost							500,000
2023 Notes [Member]
Short-Term Debt [Line Items]
Interest expense					$ 27,563		1,300,000
Aggregate principal amount				$ 216,000	$ 216,000		216,000				$ 1,836,000
Amortization of debt discount premium							100,000
Amortization of financing costs							300,000
2023 Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Payments of debt issuance costs							$ 1,100,000
2023 Notes [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate purchase price			$ 200,000
Original issue discount rate			8%
Debt instrument accrue interest rate			6%
Debt instrument conversion price			$ 1.5675
Debt instrument redemption premium percentage			10%
2023 Notes [Member] | First Closing Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate purchase price		$ 566,667
Aggregate principal amount		$ 612,000
Warrants to purchase common shares		1,255,697
Common stock, par value		$ 0.0001
2023 Notes [Member] | Second Closing Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate purchase price	$ 1,133,333
Aggregate principal amount	$ 1,224,000
Warrants to purchase common shares	2,511,394

SCHEDULE OF OUTSTANDING WARRA_2

SCHEDULE OF OUTSTANDING WARRANT (Details) - $ / shares

6 Months Ended

Jun. 30, 2024

Feb. 12, 2024

Jan. 31, 2024

Nov. 28, 2023

Oct. 25, 2023

May 12, 2023

Feb. 06, 2023

Dec. 09, 2022

Aug. 09, 2022

Jul. 01, 2022

Nov. 05, 2021

Sep. 24, 2021

Aug. 03, 2021

Jul. 02, 2021

Jun. 30, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

19,450

19,450

3,011

1,507

4,608

78,751

Warrants, exercise price

$ 1.06

$ 1.31

$ 1.5675

$ 3.64

$ 170.04

$ 170.04

$ 1,831.20

$ 1,831.20

$ 2,400

$ 2,760

Warrant expiration date

Aug. 08, 2027

Jun. 29, 2027

Nov. 04, 2026

Sep. 23, 2026

Jun. 30, 2026

December Public Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 24.07

$ 24.07

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

11,005,004

Warrants issued

3,601,752

1,323,904

2,511,394

1,255,697

3,727,813

318,451

549,993

Warrants, exercise price

$ 1.5675

$ 1.6375

$ 1.5675

$ 1.5675

$ 0.125

$ 16.80

Warrant expiration date

May 12, 2028

Nov. 28, 2028

Oct. 25, 2028

Dec. 09, 2027

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,402.40

$ 2,400

Minimum [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

3.64

$ 8.58

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,760

Maximum [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 4.86

$ 12.60

Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[1]

63,659

Warrant description

[1]

LACQ warrants

Warrant One [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[1]

$ 2,400

Warrant One [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[1]

$ 2,760

Warrant Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[2]

4,608

Exercise price

[2]

$ 1.31

Warrant description

[2]

Share subscription facility

Warrant Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[3]

4,518

Exercise price

[3]

$ 3.64

Warrant description

[3]

2021 Notes

Warrant Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[4]

38,900

Exercise price

[4]

$ 3.64

Warrant description

[4]

2022 Notes

Warrant Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[5]

549,993

Warrant description

[5]

Public offering

Warrant Five [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[5]

$ 3.64

Warrant Five [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[5]

$ 16.80

Warrant Six [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[6]

318,451

Warrant description

[6]

Public offering

Warrant Six [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[6]

$ 8.58

Warrant Six [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[6]

$ 12.60

Warrant Seven [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[7]

126,061

Exercise price

[7]

$ 4.86

Warrant description

[7]

Public offering

Warrant Eight [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[8]

2,443,187

Exercise price

[8]

$ 1.57

Warrant description

[8]

2023 Notes

Warrant Nine [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Outstanding warrant

[9]

7,455,627

Warrant description

[9]

2024 Warrants

Warrant Nine [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[9]

$ 1.06

Warrant Nine [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Exercise price

[9]

$ 1.64

[1]On June 30, 2021, as a result of the Closing of the Business Combination, the Company assumed a total of 78,751 7,782 7,310 2,400.00 2,760.00 June 30, 2026 five years 41,666 21,993 4,608 three 2,402.40 2,402.40 1.06 1,507 3,011 1,831.20 September 23, 2026 November 4, 2026 187.20 0.125 3.64 19,450 170.04 June 29, 2027 August 8, 2027 24.07 0.125 3.64 549,993 16.80 December 9, 2027. 0.125 166,667 3.64 318,451 8.58 12.60 February 2, 2028 August 7, 2028. 3,727,813 3.64 4.86 November 12, 2024 May 10, 2028 May 12, 2028 3,601,752 1.31 1,255,697 2,511,394 1.5675 October 25, 2028 November 28, 2028 1,323,904 1.5675 7,455,627 1.06 August 14, 2025 May 12, 2028 1.6375 May 12, 2028

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)	Jun. 30, 2024 $ / shares	Aug. 09, 2022 $ / shares	Jul. 01, 2022 $ / shares	Nov. 05, 2021 $ / shares	Sep. 24, 2021 $ / shares	Jul. 02, 2021 $ / shares	Jun. 30, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years						3 years	5 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3,477.60
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,400
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,760
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years					3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	110
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.5
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						3,477.60
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.13
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1,029.60
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						2,402.40
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.06
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	680.23
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 months 17 days
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	2 years 6 months 29 days
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						110
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	91.3
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	140.5
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						0.5
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.04
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	5.43
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		127.20	136.80	540	1,077.60
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		170.04	170.04	1,831.20	1,831.20
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years		5 years	5 years	5 years	5 years
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		102.8	98.9	94.1	94.1
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		3	2.9	1	1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.50
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3.64
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	2 years 3 months
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	2 years 4 months 6 days
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	133.7
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	135.4
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.6
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3.64
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years 1 month 9 days
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	126.7
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	128.6
Liability Classified Warrants Remeasured 2 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.4

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	6 Months Ended
	Feb. 12, 2024	Jun. 30, 2024	Jun. 30, 2024	Jan. 31, 2024	Dec. 31, 2023	Nov. 28, 2023	Oct. 25, 2023	May 12, 2023	Feb. 06, 2023	Dec. 09, 2022	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021	Aug. 03, 2021	Jul. 02, 2021	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized		250,000,000	250,000,000		250,000,000
Preferred stock, shares authorized		1,500,000	1,500,000		1,500,000
Preferred stock par value		$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued		0	0		0
Preferred stock, shares outstanding		0	0		0
Warrants to purchase common shares											19,450	19,450	3,011	1,507		4,608	78,751
Warrant exercise price	$ 1.31	$ 1.06	$ 1.06	$ 1.5675				$ 3.64			$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20	$ 2,400		$ 2,760
Warrant maturity date											Aug. 08, 2027	Jun. 29, 2027	Nov. 04, 2026	Sep. 23, 2026			Jun. 30, 2026
Legal fees	$ 0.3
Warrants issue, description	the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction.
Warrants to purchase common stock	252,123
Shares held in abeyance			666,144
Series A Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common shares	3,601,752
Warrant exercise price	$ 1.06
Warrant maturity date	Aug. 14, 2025
Series B Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase common shares	3,601,752
Warrant exercise price	$ 1.06
Warrant maturity date	May 12, 2028
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized								166,667
Warrants to purchase common shares	3,601,752			1,323,904		2,511,394	1,255,697	3,727,813	318,451	549,993
Share price	$ 1.31
Warrant exercise price	$ 1.6375	$ 1.5675	$ 1.5675			$ 1.5675	$ 1.5675	$ 0.125		$ 16.80
Warrant maturity date	May 12, 2028					Nov. 28, 2028	Oct. 25, 2028			Dec. 09, 2027
Proceeds from warrants	$ 4.7
Equity issuance costs	$ 5.2
Warrant Inducement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares held in abeyance		822,000	1,488,144

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance	581,314
Weighted average exercise price. beginning balance	$ 33.15
Weighted average remaining contractual term	9 years 29 days	9 years 6 months 25 days
Aggregate intrinsic value, beginning balance
Option outstanding, granted
Weighted average exercise price, granted
Aggregate intrinsic value, granted
Option outstanding, exercised
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised
Option outstanding, expired or forfeited
Weighted average exercise price, expired or forfeited
Aggregate intrinsic value, expired or forfeited
Option outstanding, ending balance	581,314	581,314
Weighted average exercise price, ending balance	$ 33.15	$ 33.15
Aggregate intrinsic value, ending balance
Option, exercisable	580,188
Weighted average exercise price, exercisable	$ 32.28
Aggregate intrinsic value, beginning balance
Option vested or expected to vest	581,314
Weighted average exercise price, vested or expected to vest	$ 33.15
Weighted average remaining contractual term, exercisable	9 years 29 days
Aggregate intrinsic value, vested or expected to vest

SCHEDULE OF COMMON STOCK FUTURE

SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shares of common stock reserved for future issuance	11,588,430
Warrant Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shares of common stock reserved for future issuance	11,005,004
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shares of common stock reserved for future issuance	581,314
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total shares of common stock reserved for future issuance	2,112

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Aug. 31, 2023	Feb. 28, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	11,588,430		11,588,430
Unrecognized stock based compensation	$ 60,092		$ 60,092
Weighted average period			11 months 12 days
General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	18,658	$ 60,394	$ 42,146	$ 156,663
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 7,891	$ 17,023	$ 17,610	$ 37,887
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance					585,796	26,725

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Apr. 25, 2024	Jun. 30, 2024	Feb. 12, 2024	Jan. 31, 2024	Nov. 28, 2023	Oct. 25, 2023	Oct. 23, 2023	May 12, 2023	Dec. 09, 2022	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021	Aug. 03, 2021	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants exercisable		0.4
Warrant, exercise price		$ 1.06	$ 1.31	$ 1.5675				$ 3.64		$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20	$ 2,400	$ 2,760
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant, exercise price		$ 1.5675	$ 1.6375		$ 1.5675	$ 1.5675		$ 0.125	$ 16.80
Warrant, expiration date	Apr. 25, 2025
Securities Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt financing amount		$ 0.2
Warrant, exercise price							$ 1.5675